Beta2 adrenergic receptor (ADRβ2) haplotype pair (2/4) is associated with severe asthma

PLoS One. 2014 Apr 1;9(4):e93695. doi: 10.1371/journal.pone.0093695. eCollection 2014.

Abstract

Background: β2 adrenergic receptor (ADRβ2) polymorphisms including ADRβ2+46G>A have been reported to cause adverse outcomes in mild asthmatics. The extent to which ADRβ2 polymorphisms and in particular their haplotypes contribute to severe asthma is unknown.

Objective: To determine the association of ADRβ2 polymorphisms and haplotypes with asthma severity.

Methods: Caucasians (n = 2979) were genotyped for 11 ADRβ2 polymorphisms. The cohort (mean age 39.6, 60% female) included 2296 non-asthmatics, 386 mild asthmatics, 172 moderate asthmatics and 125 severe asthmatics. Haplotype frequency and haplotype pair for each subject was determined using the PHASE algorithm.

Results: The three asthmatic cohorts were comparable in age and gender but were distinguishable from each other in terms of symptoms, spirometry, medication use and health care utilisation (p <0.001). None of the polymorphisms showed a genotypic or allelic association with asthma diagnosis or severity. Nine haplotypes were identified and no association was found with asthma diagnosis or severity per se. Haplotype pair 2/4 was associated with asthma severity (Trend Test, OR 1.42, p = 0.0008) but not with asthma per se. Prevalence of haplotype pair 2/2 appeared to decrease with asthma severity (Trend Test, OR 0.78, p = 0.067). Two new haplotypes were identified, occurring exclusively in asthmatics at a frequency of ≥ 1%. In addition, a positive association between carriage of ADRβ2 +523*C and increased risk of atopy was discovered.

Conclusions: ADRβ2 haplotype pair 2/4 is associated with severe asthma and is consistent with findings of poor bronchodilator response in mild asthmatics who are also haplotype 2/4.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Alleles
  • Asthma / genetics*
  • Asthma / pathology
  • Bronchodilator Agents / administration & dosage
  • Female
  • Genetic Association Studies*
  • Genotype
  • Haplotypes / genetics*
  • Humans
  • Linkage Disequilibrium
  • Male
  • Middle Aged
  • Receptors, Adrenergic, beta-2 / genetics*
  • Spirometry

Substances

  • Bronchodilator Agents
  • Receptors, Adrenergic, beta-2

Grants and funding

The funding for this report was derived from the Lung Institute of Western Australia as part of a PhD project. There were no external sources of funding that would otherwise affect the study design, data collection and analysis, decision to publish or presentation of the manuscript.